<DOC>
	<DOCNO>NCT02493751</DOCNO>
	<brief_summary>This Phase 1b , open-label , multi-center , multiple-dose trial design estimate maximum tolerate dose ( MTD ) select recommend phase 2 dose ( RP2D ) avelumab ( MSB0010718C ) combination axitinib ( AG-013736 ) . Once MTD avelumab administer combination axitinib estimate ( dose find portion ) , dose expansion phase open characterize combination term safety profile , anti tumor activity , pharmacokinetics , pharmacodynamics biomarker modulation .</brief_summary>
	<brief_title>A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer ( JAVELIN Renal 100 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically cytologically confirm advanced RCC clear cell component Primary tumor resect Availability recent formalinfixed , paraffinembedded ( FFPE ) tumor tissue block de novo tumor biopsy screening ( biopsied tumor lesion RECIST target lesion ) . Alternatively , recently obtain archival FFPE tumor tissue block ( cut slide ) primary metastatic tumor resection biopsy provide follow criterion meet : 1 ) biopsy resection perform within 1 year enrollment AND 2 ) patient receive intervening systemic anticancer treatment time tissue obtain enrollment onto current study . If FFPE tissue block provide per documented regulation , , 15 unstained slide ( 10 minimum ) acceptable . Availability archival FFPE tumor tissue block primary diagnosis specimen ( available provide per ) . If FFPE tissue block provide , 15 unstained slide ( 10 minimum ) acceptable At least one measureable lesion define RECIST version 1.1 previously irradiate . Age ≥18 year ( ≥ 20 year Japan ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow function , renal liver function Prior systemic therapy direct advanced RCC . Prior adjuvant neoadjuvant therapy RCC disease progression relapse occur within 12 month last dose treatment Prior immunotherapy IL2 , IFNα , anti PD 1 , anti PD L1 , anti PD L2 , anti CD137 , anti cytotoxic T lymphocyte associate antigen 4 ( CTLA 4 ) antibody ( include ipilimumab ) , antibody drug specifically target T cell co stimulation immune checkpoint pathway Prior therapy axitinib well prior therapy VEGF pathway inhibitor . Known severe hypersensitivity reaction monoclonal antibody ( Grade ≥3 ) , history anaphylaxis . Any following previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , deep vein thrombosis symptomatic pulmonary embolism . Vaccination within 4 week first dose avelumab trial prohibit except administration inactivate vaccine ( example , inactivate influenza vaccine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cancer , renal cell cancer , kidney disease , kidney neoplasm , axitinib</keyword>
</DOC>